4.4 Review

Influenza vaccination for elderly, vulnerable and high-risk subjects: a narrative review and expert opinion

期刊

INTERNAL AND EMERGENCY MEDICINE
卷 -, 期 -, 页码 -

出版社

SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s11739-023-03456-9

关键词

Influenza; Burden of disease; Influenza vaccines; Aged; Cardiovascular diseases; Diabetes mellitus; Chronic diseases

向作者/读者索取更多资源

This review summarizes the impact of influenza on vulnerable populations, emphasizing the benefits of influenza vaccination in preventing severe illness and complications. The efficacy, effectiveness, and safety of vaccines suitable for older adults in Italy are also reviewed. Although high-dose and adjuvanted influenza vaccines have been developed to enhance immune responses in older adults, vaccination coverage in high-risk populations remains suboptimal. Healthcare professionals play an important role in increasing vaccination rates.
Influenza is associated with a substantial health burden, especially in high-risk subjects such as older adults, frail individuals and those with underlying chronic diseases. In this review, we summarized clinical findings regarding the impact of influenza in vulnerable populations, highlighted the benefits of influenza vaccination in preventing severe illness and complications and reviewed the main evidence on the efficacy, effectiveness and safety of the vaccines that are best suited to older adults among those available in Italy. The adverse outcomes associated with influenza infection in elderly and frail subjects and those with underlying chronic diseases are well documented in the literature, as are the benefits of vaccination (mostly in older adults and in patients with cardiovascular diseases, diabetes and chronic lung disease). High-dose and adjuvanted inactivated influenza vaccines were specifically developed to provide enhanced immune responses in older adults, who generally have low responses mainly due to immunosenescence, comorbidities and frailty. These vaccines have been evaluated in clinical studies and systematic reviews by international immunization advisory boards, including the European Centre for Disease Prevention and Control. The high-dose vaccine is the only licensed influenza vaccine to have demonstrated greater efficacy versus a standard-dose vaccine in preventing laboratory-confirmed influenza in a randomized controlled trial. Despite global recommendations, the vaccination coverage in high-risk populations is still suboptimal. All healthcare professionals (including specialists) have an important role in increasing vaccination rates.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据